A bankruptcy declaration and large settlement are supposed to bring some degree of closure. Purdue Pharma LP’s bankruptcy filing and $10 billion plan to settle litigation over its alleged role in fueling the opioid crisis, announced Sept. 15, may not provide much. The proposal from Purdue, which made billions selling the highly popular opioid OxyContin,…
This article is available only to PBN Subscribers. To get unlimited access, please subscribe by following the link below.
Already a subscriber? Login now
Want to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.